![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Galitzky, M Reverte, C Carpene, M Lafontan and M Berlan
Institut National de la Sante et de la Recherche Medicale Unite 317, Faculte de Medecine, Universite Paul Sabatier, France.
The existence of beta 3-adrenoceptors in adipose tissue and their involvement in the control of lipolysis was investigated in dog. Selective beta 3-adrenergic agonists (BRL 37344, SR 58611A and CGP 12177) and catecholamines (isoproterenol and norepinephrine) activated lipolysis in isolated adipocytes (order of potency: isoproterenol > BRL 37344 > norepinephrine > CGP 12177 > SR 58611A). The lipolytic effect of 0.05 microM BRL 37344 was antagonized by the nonselective beta-AR antagonists, but the selective beta 1-(CGP 20712A) and beta 2-(ICI 118551) antagonists were ineffective. Infused to conscious dogs, beta 3- adrenergic agonists increased plasma nonesterified fatty acids levels with an order of potency equivalent to that defined in lipolysis. The lipomobilizing effect induced by the administration of an alpha 2- antagonist (0.01 mg/kg RX 821002 i.v.) was suppressed by bupranolol (0.5 mg/kg) or the combination of CGP 20712A and ICI 118551 (0.25 mg/kg each). The effect of 0.05 mg/kg RX 821002 was only partially suppressed by the same beta-antagonist combination, whereas bupranolol totally abolished it. At 0.5 mg/kg, the RX 821002 effect was not modified by beta-antagonists. The lipomobilization due to infusion of catecholamines (0.1, 0.5 or 5 micrograms/kg/min norepinephrine or 5 micrograms/kg/min epinephrine) was always suppressed by bupranolol or the combination of selective beta-antagonists. Thus dog adipocytes express functional beta 3-ARs. Their stimulation induces lipid mobilization. The lipomobilization of exogenously administered catecholamines is due only to the recruitment of beta 1- or beta 2-ARs. However, endogenous catecholamines released after sympathetic nervous system activation could stimulate beta 3-ARs in adipocytes only if a high level of sympathetic nervous system activity is realized.
This article has been cited by other articles:
|
|
 |
|
  B. Rozec, M. Erfanian, K. Laurent, J.-N. Trochu, and C. Gauthier Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1532 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pelat, P. Verwaerde, J. Galitzky, M. Lafontan, M. Berlan, J.-M. Senard, and J.-L. Montastruc High Isoproterenol Doses Are Required to Activate beta 3-Adrenoceptor-Mediated Functions in Dogs J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Mittelman, G. W. Van Citters, E. L. Kirkman, and R. N. Bergman Extreme Insulin Resistance of the Central Adipose Depot In Vivo Diabetes, March 1, 2002; 51(3): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gauthier, G. Tavernier, J.-N. Trochu, V. Leblais, K. Laurent, D. Langin, D. Escande, and H. Le Marec Interspecies Differences in the Cardiac Negative Inotropic Effects of beta 3-Adrenoceptor Agonists J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 687 - 693. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
